



(11) **EP 3 154 517 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/00 (2006.01) **A61K 8/49** (2006.01)
A61Q 19/00 (2006.01) **A61K 47/14** (2017.01)
A61K 9/06 (2006.01) **A61K 9/107** (2006.01)
A61K 31/4174 (2006.01)

(48) Corrigendum issued on:
03.06.2020 Bulletin 2020/23

(86) International application number:
PCT/US2015/035420

(45) Date of publication and mention
of the grant of the patent:
22.04.2020 Bulletin 2020/17

(87) International publication number:
WO 2015/191917 (17.12.2015 Gazette 2015/50)

(21) Application number: **15738161.7**

(22) Date of filing: **11.06.2015**

(54) **STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES**

STABILISIERTE OXYMETAZOLINFORMULIERUNGEN UND DEREN VERWENDUNG
FORMULATIONS D'OXYMÉTAZOLINE STABILISÉES ET LEURS UTILISATIONS

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **WARNER, Kevin**
Anaheim, California 92807 (US)
- **ZHANG, Steven**
Newton, Massachusetts 02461 (US)
- **AHLUWALIA, Gurpreet**
Tustin, California 92705 (US)
- **KUANG, Amy**
Irvine, California 92620 (US)

(30) Priority: **11.06.2014 US 201462010838 P**
28.10.2014 US 201462069624 P

(43) Date of publication of application:
19.04.2017 Bulletin 2017/16

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(73) Proprietor: **EPI Health, LLC**
Charleston, SC 29403 (US)

(72) Inventors:
• **SARPOTDAR, Pramod**
Huntington Beach, CA 92649 (US)

(56) References cited:
WO-A2-2012/075319 US-A1- 2012 208 858

EP 3 154 517 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).